Immunohistochemistry in Cancer and Inflammation

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: closed (25 September 2023) | Viewed by 2035

Special Issue Editors


E-Mail Website
Guest Editor
Section of Anatomy and Histology, Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy
Interests: immunohistochemistry; cell culture; odontostomatology; occupational medicine; urology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Section of Anatomy and Histology, Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy
Interests: biomarkers; toxicology; odontostomatology; epidemiology; inflammation; cancer

Special Issue Information

Dear Colleagues,

We are pleased to invite you to contribute to this Special Issue dedicated to immunohistochemical applications related to neoplastic and inflammatory diseases.Immunohistochemistry plays a relevant role in the diagnosis and prognosis of various cancer forms, determining biomarker tumor expressions. Inflammatory processes are often implicated in the development of cancer, especially in the stages of cell transformation, tumor promotion, survival, proliferation, invasion, angiogenesis and metastasis.

Conversely, neoplastic cells may induce the release of pro-inflammatory cytokines causing the onset of inflammation and immunodepression.

The present Special Issue aims to shed light on recent findings describing the key molecular role of inflammation cellular pathways and cancer development. New prognostic and predictive factors for inflammatory or neoplastic diseases could be reported to help clinicians in diagnostic and treatment procedures.

In this Special Issue, original research articles and reviews are welcome. Research areas may include clinicopathological studies as well as in vitro and in vivo experiments with cell culture and animals. A limited number of relevant case reports will also be accepted.

We look forward to receiving your contributions.

Prof. Dr. Carla Loreto
Prof. Dr. Claudia Lombardo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • inflammation
  • immunohistochemistry
  • biomarkers
  • prognostic and predictive factors

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 1821 KiB  
Article
Expression of IDO1 and PD-L2 in Patients with Benign Lymphadenopathies and Association with Autoimmune Diseases
by Maysaa Abdulla, Christer Sundström, Cecilia Lindskog and Peter Hollander
Biomolecules 2023, 13(2), 240; https://doi.org/10.3390/biom13020240 - 27 Jan 2023
Cited by 1 | Viewed by 1581
Abstract
The expression patterns of IDO1 and PD-L2 have not been thoroughly investigated in benign lymphadenopathies. The aim with this study was to elucidate how IDO1 and PD-L2 are expressed in benign lymphadenopathies in patients with autoimmune diseases (AD) compared to patients without AD. [...] Read more.
The expression patterns of IDO1 and PD-L2 have not been thoroughly investigated in benign lymphadenopathies. The aim with this study was to elucidate how IDO1 and PD-L2 are expressed in benign lymphadenopathies in patients with autoimmune diseases (AD) compared to patients without AD. Formalin-fixed paraffin-embedded lymph nodes from 22 patients with AD and 57 patients without AD were immunohistochemically stained to detect IDO1 and PD-L2. The material was previously stained with EBER in situ hybridization to detect cells harboring the Epstein–Barr virus (EBV). IDO1 and PD-L2 were generally expressed by leukocytes to low degrees, while follicular IDO1+ cells were very rare. IDO1+ cells in single germinal centers were detected in five patients, and there was a high co-occurrence of follicular EBV+ cells in these cases (three of five patients). There were also significant correlations between interfollicular EBV+ cells and interfollicular IDO1+ cells (Spearman rho = 0.32, p = 0.004) and follicular IDO1+ cells (Spearman rho = 0.34, p = 0.004). High or low amounts of IDO1+ or PD-L2+ cells were not statistically significantly associated with patients with AD. However, the lymphadenopathy with the highest amount of interfollicular IDO1+ cells, which was also the only lymphadenopathy in which endothelial cells expressed IDO1, was in a patient with sarcoidosis. This study further supports that the EBV induces the expression of IDO1 and our findings should be recognized by future studies on IDO1 and PD-L2 in inflammatory and malignant conditions. Full article
(This article belongs to the Special Issue Immunohistochemistry in Cancer and Inflammation)
Show Figures

Graphical abstract

Back to TopTop